| Joy S Yoder, CNM | |
|
175 Martin Ave, Suite 125, Ephrata, PA 17522-1761 | |
| (717) 721-5700 | |
| (717) 721-5712 |
| Full Name | Joy S Yoder |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 175 Martin Ave, Ephrata, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790083640 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | MW010237 (Pennsylvania) | Primary |
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
Today's summit on the future of health care in this country, while far from resolving all of the differences between Republicans and Democrats on reforming our broken health insurance system, was a huge win for the American people.
Sustainability and Transformation Partnerships, Clinical Commissioning Groups and primary care practices must all work together to improve outcomes for patients with Chronic Kidney Disease (CKD), according to the national Chronic Kidney Disease Audit published today.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joy S Yoder, CNM 601 Memory Ln, York, PA 17402-2231 Ph: (717) 851-1405 | Joy S Yoder, CNM 175 Martin Ave, Suite 125, Ephrata, PA 17522-1761 Ph: (717) 721-5700 |
News Archive
Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix's Parkinson's disease program. The new allowances to U.S. Patent Number 765,446, entitled "Glutamic acid decarboxylase (GAD) based delivery systems," broaden the patent's coverage beyond Parkinson's disease to include the use of GAD65 in the treatment of other neurological and related disorders.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
Today's summit on the future of health care in this country, while far from resolving all of the differences between Republicans and Democrats on reforming our broken health insurance system, was a huge win for the American people.
Sustainability and Transformation Partnerships, Clinical Commissioning Groups and primary care practices must all work together to improve outcomes for patients with Chronic Kidney Disease (CKD), according to the national Chronic Kidney Disease Audit published today.
› Verified 7 days ago
Danica Beebe, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 175 Martin Ave, Suite 125, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-721-5712 | |
Ms. Lucinda Grace Manges, C.N.M Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 175 Martin Ave, Suite 125, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-721-5712 | |
Mrs. Lori Jean Conley, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 175 Martin Ave, Suite 125, Ephrata, PA 17522 Phone: 717-751-5700 Fax: 717-721-5712 | |
Ms. Karen Ann Crouse, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 175 Martin Ave, Suite 125, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-721-5712 |